USP7:a promising target for cancer therapy
Yaqi Meng1,2Erdong Li1,2Na Li1,2Jingchao Xin1,2Chongnan Bao1,2Peng Yang1,2Jiaxin Zheng1,2Qiurong Zhang1,2Hongmin Liu1,2
1. School of Pharmaceutical Sciences,Zhengzhou University2. Collaborative Innovation Center of New Drug Research and Safety Evaluation
摘要：The deubiquitinating enzyme,ubiquitin-specific protease7（USP7）,plays a pivotal role in regulating the cellular processes.The aberrant USP7 has been implicated in the occurrence of cancer,including human prostate cancer,multiple myeloma and chronic lymphocytic leukemia[1].Besides the expression level of the USP7 was also directly associated with the tumor aggressiveness and predicted the poor prognosis.In particularly,USP7 has been reported regulation of p53-pathway[2].Thus,USP7 has attracted increasing attention as a validated oncology target for cancer therapy within the decades.Although several USP7 inhibitors had been reported（Fig.1）,there are no clinical candidates so far[3].Given the importance of USP7 which acts on the oncogene and the urgent to discovery the novel USP7 inhibitors,modulation of USP7 activity has the potential to offer therapeutic benefit for the treatment of cancer.
会议名称：
第11届世界华人药物化学研讨会（ISCMC 2018）
会议时间：
2018-08-24
会议地点：
中国河南郑州
- 专辑：
医药卫生
- 专题：
药学
- 分类号：
R91
引文网络
相关推荐
- 相似文献
- 读者推荐
- 相关基金文献
- 关联作者
- 相关视频
